BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer and BioNTech announced a 90% effective vaccine for COVID-19. Shares are soaring on the news, gaping up from pre-news $90 to current $101.66.

BioNTech COVID-19 Vaccine Sets Up >50% Annual Yield With 19% Downside Protection

Pfizer

Although the details of interim data from the Phase 3 trials of Pfizer Inc's (NYSE: PFE) COVID-19 vaccine study rea unclear, the results represent “a solid win” for the company, according to BofA Securities. The Pfizer Analyst: Geoff Meacham maintained a Neutral rating on Pfizer with an unchanged $39 price target.

Pfizer Analyst: Coronavirus Vaccine Moving Closer To Emergency Use Authorization

U.S. Health and Human Services Secretary Alex Azar said on Monday it would take several weeks for U.S. regulators to receive and then process data on Pfizer Inc's vaccine for the coronavirus before the government could potentially approve it.

Potential approval of Pfizer vaccine still several weeks away: U.S. official

Pfizer (PFE Quick QuotePFE - Free Report) may have discovered the COVID-19 vaccine that the world has been waiting for since this pandemic began. The equity markets are soaring this morning, being led by the cyclical underperformers, while 2020's parabolic tech stocks take a seat on the sidelines for once.

What A Vaccine Means For The Stock Market

"I had zero worry" going into the trial whether the vaccine was going to be safe, Isaacson told CNBC. But he does not know if he got the vaccine or the placebo.

Walter Isaacson, a participant in Pfizer's Covid vaccine trial, describes what it's like

AstraZeneca

Johnson & Johnson

Moderna

Novavax

A safe and effective Covid-19 vaccine is seen by investors and policymakers as a solution to get the global economy back on track.

Coronavirus vaccine frontrunner Pfizer delivers key trial data – here's where the other vaccines stand

Shares of BNTX stock are flying on Monday after BioNTech and Pfizer announced extremely positive results from their Covid-19 vaccine trials. The post BioNTech News: 5 Things for BNTX Stock Investors to Know appeared first on InvestorPlace.

BioNTech News: 5 Things for BNTX Stock Investors to Know

Talk about starting out a new week with a renewed sense of optimism! Market indexes in Monday's pre-market trading are practically off the charts: the Dow +1600 points, the Nasdaq +140 points and the S&P 500 +160.

Positive News on COVID-19 Vaccine

A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.

Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX

On Monday, the German biotech and its partner Pfizer announced that initial data shows their COVID-19 vaccine candidate is more than 90% effective.

Why BioNTech Stock Is Skyrocketing Today After Gaining 23% Last Month

The two companies reported great news for COVID-19 vaccine candidate BNT162b2.

Why Pfizer and BioNTech Stocks Are Soaring Today

The European Union drug regulator said on Monday it had not yet received results from large-scale trials on the COVID vaccines being developed by Pfizer and BioNTech and that it was currently assessing earlier data on the quality of the shot.

EU drug regulator says it is assessing early data from Pfizer COVID vaccine

Shares of both Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

Efficacy in Pfizer and BioNTech COVID-19 Study Rocks the Market

BioNTech and Pfizer Inc.'s COVID-19 vaccine candidate is the first to demonstrate it can protect most people from contracting symptomatic infections with the virus in a Phase 3 clinical trial — an announcement that puts the companies in the lead to bring to market the first COVID-19 vaccine in the U.S.

BioNTech and Pfizer say their COVID-19 vaccine candidate is 90% effective

Two drug makers making waves on Wall Street this morning are Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX).

Two Drugmakers Surging After COVID-19 Vaccine Announcement

"I think we need to remember that we have perhaps a brief, but very hard stretch, ahead of us" without a widely available Covid-19 vaccine, Gottlieb told CNBC.

Dr. Scott Gottlieb, a Pfizer director and ex-FDA chief, says Covid vaccine won't help immediately

The European Union is about to sign a contract for millions of doses of the COVID-19 vaccine being developed by Pfizer and BioNTech , a prominent EU lawmaker said on Monday.

EU about to sign supply deal for Pfizer COVID vaccine: lawmaker

Pfizer stock is rallying higher Monday on coronavirus vaccine results, and it's taking the rest of the stock market with it. The post Vaccine News: Pfizer Stock Soars 15% on Coronavirus Trial Results appeared first on InvestorPlace.

Vaccine News: Pfizer Stock Soars 15% on Coronavirus Trial Results

A phase 3 clinical trial found BNT162b2 more than 90% effective at preventing COVID-19 at the first interim analysis.

Coronavirus Vaccine Candidate From Pfizer and BioNTech Leaps Over Efficacy Hurdle

Pfizer stock rocketed early Monday after the pharma giant said its coronavirus vaccine was more than 90% effective in a Phase 3 study. The post Pfizer Stock Rockets As Coronavirus Vaccine Proves 90% Effective appeared first on Investor's Business Daily.

Pfizer Stock Rockets As Coronavirus Vaccine Proves 90% Effective

In a statement on Monday, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said that their jointly developed COVID-19 vaccine is effective in more than 90% of the patients. The two drug manufacturers are the first ones to publish successful trial data, taking the world a step closer to winning the battle against the Coronavirus pandemic that has so far infected more than 50 million people worldwide and caused over 1.2 million deaths.

Pfizer/BioNTech COVID-19 vaccine is effective in more than 90% of cases

Pfizer CEO Albert Bourla said Monday that he would like to be among the first to take a coronavirus vaccine to ease public concerns about vaccine safety.

Pfizer CEO says he would take coronavirus vaccine first to ease public concern

As expected, Pfizer Inc. (NYSE: PFE)/BioNTech SE – ADR (NASDAQ: BNTX) became the first among the vaccine developers to release interim results from the largescale final phase clinical results, with the first interim analysis yielding solid efficacy results. What Happened: The mRNA vaccine candidate, codenamed BNT162b2, developed by the combo was found to be more than 90% effective in preventing COVID-19 in healthy volunteers, Pfizer/BioNTech said, citing first interim analysis of the large-scale Phase 3 study.

Pfizer-BioNTech's COVID-19 Vaccine Is 90% Effective, EUA Filing Likely By Late November

Markets spent weeks obsessing over the outcome of the US election. Now that it's clear Joe Biden will be the next president, Wall Street is moving on.

Pfizer vaccine news is exactly what investors were craving

Britain expects to have 10 million doses of Pfizer/BioNTech's candidate COVID-19 vaccine available by the end of the year if regulators approve it, Prime Minister Boris Johnson's spokesman said on Monday, following positive clinical trial results.

News for BioNTech SE Stock (BNTX)